Alle Storys
Keine Story von Intercell AG mehr verpassen.

Intercell AG

Intercell receives "The Vaccine Industry Excellence Award"

Wien (euro adhoc) -

» Intercell's Hepatitis C vaccine candidate was awarded in the 
   of "Best New Therapeutic Vaccine" at the World Vaccine 
» Intercell's therapeutic Hepatitis C vaccine 
successfully concluded  
   Phase II clinical trials in February 2008
  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
Vienna (Austria), April 24, 2008 - In the course
of the World Vaccine Congress in Washington D.C., USA, Intercell was 
awarded "The Vaccine Industry Excellence Award" in the category "Best
New Therapeutic Vaccine" for its therapeutic Hepatitis C (HCV) 
vaccine candidate.
Earlier this year, Intercell's therapeutic vaccine candidate against 
HCV successfully concluded Phase II clinical trials. The novel 
vaccine is designed to stimulate T-cell responses against viral 
protein structures conserved throughout the major HCV genotypes in 
order to reduce viral load in the blood of chronically infected 
"We are pleased to receive this award for our novel therapeutic 
Hepatitis C vaccine. The latest Phase II data provides a strong base 
to further strengthen our Hepatitis C franchise and to accelerate our
efforts towards a most valuable potential component in a combination 
treatment for HCV," stated Alexander von Gabain, Chief Scientific 
Officer of Intercell.
To improve and accelerate the development of a therapeutic Hepatitis 
C vaccine, Intercell and its partner Novartis will take advantage of 
an enlarged antigen portfolio and of IC31®, Intercell´s 
second-generation adjuvant.
With representatives from over 200 individual companies, the "World 
Vaccine Congress", taking place in Washington D.C. (USA) from April 
21-24, 2008, is one of the largest and most important vaccine 
industry meetings this year.
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303

Branche: Biotechnology
ISIN: AT0000612601
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG